Key Points Regeneron's latest financial results were strong. The company is finding ways to overcome a recent patent cliff. Despite more challenges on the horizon, the biotech's prospects look bright. 10 stocks we like better than Regeneron Pharmaceuticals › Regeneron Pharmaceuticals ' (NASDAQ: REGN) shares climbed well above $1,000 two years ago, reaching all-time highs. However, they have dropped significantly from those levels over the past 24 months and now sit slightly below $800 apiece. What has happened to Regeneron? Is the stock a great buy at current levels? Let's find out. Recent financial results In the second quarter, Regeneron's revenue increased by 17% year over year to $4.3 billion.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.